PAM
VIRX

Panagora Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Panagora Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-48
Closed -$30K – 2440
2015
Q2 		$30K Buy
+48
New +$25.5K ﹤0.01% 2241
2014
Q3 		– Sell
-5
Closed -$7K – 2367
2014
Q2 		$7K Sell
5
-28
-85% -$32.5K ﹤0.01% 2296
2014
Q1 		$45K Buy
33
+28
+560% +$32.6K ﹤0.01% 2114
2013
Q4 		$5K Hold
5
– – ﹤0.01% 2156
2013
Q3 		$5K Sell
5
-101
-95% -$108K ﹤0.01% 2283
2013
Q2 		$116K Buy
+106
New +$118K ﹤0.01% 1817

Other funds holding VIRX

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Panagora Asset Management's VIRX Position: Q3 2015 in Review

Panagora Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 48 shares — an estimated $30K sold.

Panagora Asset Management first reported a position in VIRX in Q2 2013 and held it in 6 quarters. The position peaked at $116K in Q2 2013. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

  • Panagora Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Panagora Asset Management sold 48 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $30K.
  • Panagora Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
  • Panagora Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $116K in Q2 2013.
  • 59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Panagora Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.